FBLG — FibroBiologics, Inc. Common Stock
$0.9500-6.86%
Last close: · regular session
After-hours $0.9600 +1.05% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for FBLG in the TickerWise workspace.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 13
- Website: https://www.fibrobiologics.com
Latest SEC filings for FBLG
- EFFECT
- EFFECT
- D
- POS AM
- POS AM
- 8-K
- SCHEDULE 13G
- 10-Q
- 8-K
- EFFECT
Latest FBLG news
- FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs Read article
- FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.